Cannabis Use Disorder Market Research Report 2025-2035: Pharmaceutical R&D Focus Intensifies on Targeted Therapies - Aelis Farma Advances AEF0117, a Selective CB1 Modulator, in Phase IIb Development
Dublin, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The "Cannabis Use Disorder Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035" report has been added to ResearchAndMarkets.com's offering.
The global cannabis use disorder market is characterized by significant interest from pharmaceutical companies focusing on developing and commercializing drugs specifically targeting cannabis dependence. Aelis Farma is a key player with its investigational drug AEF0117, a selective CB1 receptor modulator, currently in Phase IIb trials for cannabis use disorder.
Additionally, Anebulo Pharmaceuticals is developing ANEB-001, a 5-HT2C receptor agonist, for treating cannabis dependence, currently undergoing clinical trials. The market is expected to grow as these investigational drugs progress through clinical development, bringing more targeted treatment options to the forefront for individuals struggling with cannabis addiction.
The global cannabis use disorder market is evolving rapidly due to the growing recognition of cannabis use as a serious public health issue. Despite the lack of FDA-approved medications specifically for cannabis use disorder, various investigational drugs are being developed to address this condition, including cannabinoid receptor antagonists and serotonin-based therapies.
The market is driven by increasing demand for effective treatment options, rising awareness of cannabis use disorder's impact, and growing research funding. However, challenges such as regulatory hurdles, stigma, and a lack of standardized treatment protocols remain. As the market progresses, new therapies, including those targeting cannabis withdrawal symptoms, are expected to emerge, creating opportunities for both established and new pharmaceutical companies.
Global Cannabis use disorder Market Regional Overview
The global cannabis use disorder market is experiencing varied growth across different regions, driven by factors such as legalization trends, healthcare infrastructure, and awareness of addiction treatment.
In North America, particularly in the U.S. and Canada, the market is seeing significant growth due to increasing cannabis legalization and rising awareness of cannabis use disorder. The region's strong healthcare infrastructure, combined with ongoing research and development, is propelling the adoption of new therapies. With regulatory bodies like the FDA actively involved in reviewing investigational treatments, North America is expected to lead the market in terms of both treatment advancements and adoption.
Europe is following closely, driven by increasing support for digital health and addiction treatment programs. Although cannabis legalization is more restricted, many European countries are improving their healthcare policies to address addiction and substance use disorders. With growing public health campaigns, Europe is gradually becoming a significant market for cannabis use disorder treatment solutions.
In Asia-Pacific, the market is nascent, but countries like Japan, South Korea, and Australia are beginning to show interest in developing treatment solutions, primarily driven by rising drug dependence concerns.
Rest-of-the-World regions are seeing slower adoption, influenced by cultural attitudes, varying levels of cannabis regulation, and healthcare system limitations. However, awareness campaigns and future market potential suggest gradual growth in regions such as Latin America, the Middle East, and Africa.
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: This report offers valuable insights into emerging trends and research in cannabis use disorder treatment, helping organizations identify innovation opportunities and refine product offerings. By understanding the latest developments in investigational therapies, companies can adapt and enhance their treatment solutions.
Competitive Strategy: By analyzing key market players, ongoing clinical trials, and regulatory progress, this report enables organizations to assess market dynamics, identify competitive gaps, and develop strategies to strengthen their position. It provides actionable intelligence for improving market share and staying ahead in a rapidly evolving industry.
Demand Drivers and Limitations
The following are the drivers for the global Cannabis Use Disorder market:
The global cannabis use disorder market is expected to face some limitations too, due to the following challenges:
Impact
Key Topics Covered:
Executive Summary
Scope of Study
Research Methodology
1. Global Cannabis Use Disorder Market: Industry Outlook
1.1 Market Overview
1.2 Epidemiological Analysis
1.3 Clinical Trials
1.4 Regulatory Landscape / Compliance
1.5 Key Trends
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2. Global Cannabis Use Disorder Market (By Region), $Million, 2023-2035
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.2.1 North America Cannabis Use Disorder Market, by Country
2.1.2.1.1 U.S.
2.1.2.1.2 Canada
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.2.1 Europe Cannabis Use Disorder Market, by Country
2.2.2.1.1 U.K.
2.2.2.1.2 Germany
2.2.2.1.3 France
2.2.2.1.4 Italy
2.2.2.1.5 Spain
2.2.2.1.6 Rest-of -Europe
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.2.1 Asia-Pacific Cannabis Use Disorder Market, by Country
2.3.2.1.1 Japan
2.3.2.1.2 Rest-of-Asia-Pacific
2.4 Rest-of-the-World
2.4.1 Market Dynamics
2.4.2 Market Sizing and Forecast
3. Global Cannabis Use Disorder Market - Competitive Landscape and Company Profiles
3.1 Key Developments and Strategies
3.1.1 Funding Activities
3.1.2 Mergers and Acquisitions
3.1.3 Regulatory Approvals
3.1.4 Partnerships, Collaborations and Business Expansions
3.2 Company Profiles
3.2.1 Aelis Farma
3.2.1.1 Company Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers/End Users
3.2.1.4 Analyst View
3.2.2 Anebulo Pharmaceuticals
3.2.2.1 Company Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers/End Users
3.2.2.4 Analyst View
3.2.3 Others
4. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/odmqg6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.